Kratom and 7-OH Dependence Cases Surge at US Addiction Clinics
Treatment centers report a sharp rise in kratom and especially 7-OH dependence, with Boulder Care seeing patient share increase from 3% to 14% within eleven months. 7-OH acts as a direct opioid receptor agonist, producing withdrawal syndromes comparable to traditional opioids. Regulatory actions at federal and state levels are underway, but evidence on net population impact remains limited to observational clinic data.
Next steps include expanded post-marketing surveillance by FDA and prospective cohort studies tracking dependence incidence after state bans. Such data will clarify whether access restrictions reduce overall harm or simply shift users toward formal treatment systems.
DEA: Final rule restricting 7-OH above trace levels will be published by Q2 2027, leading to measurable decline in retail sales within six months.
Sources (3)
- [1]STAT News via MedicalXpress(https://medicalxpress.com/news/2026-09-kratom-cases-climb-sharply.html)
- [2]NIDA Kratom Research Overview(https://nida.nih.gov/research-topics/kratom)
- [3]FDA 7-OH Safety Communication(https://www.fda.gov/news-events/press-announcements)